

## INDEX

---

Note: AF stands for atrial fibrillation.  
Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.  
Clinical trials and studies are indexed  
under the acronym of the name.

A to Z Trial, 95  
AADs. See *Antiarrhythmic drugs (AADs)*.  
Ablation. See also *Catheter ablation; Surgical ablation*.  
catheter ablation, 13, 164-184  
    success rate, 133  
    clinical studies, 118t-119t  
    EPS for targeting sites for, 79  
    with pacemaker implantation, 270-272  
    surgical ablation, 184-187, 185, 186t, 270-272, 279, 381  
ACC/AHA/ESC Guidelines  
    AF classification, 17-20  
    diagnostic tests, 72t-73t  
    pharmacologic cardioversion, 152  
ACC/AHA/HRS Guidelines  
    ADDs for repeat cardioversion, 145, 145t  
    antithrombotic therapy, 289, 295  
    catheter ablation, 181-184  
    device guidelines, 103-104  
    electrical cardioversion, 134-135  
    prevention of AF, 128  
ACE inhibitors, 88-93, 89, 104, 305  
    actions of, 90t  
    in combination with AADs, 214  
Acebutolol, 260t  
Acetaminophen, 317, 318t  
Acetylcholine, 40  
ACT I-IV trials, 161-163  
ACTIVE-A study, 313, 314t, 358  
ACTIVE-W trial, 310, 358  
Acute decompensated heart failure (ADHF), 65  
ACUTE trial, 361-362  
ACUTE II study, 363  
Adenosine, 57  
ADONIS, 226, 229  
Adrenergic tone, high, 258  
AF-CHF trial, 122, 126-127  
AF Symptoms Study, 272  
AFASAK, 293, 304  
AFFECTS Registry, 311

AFFIRM trial, 31, 116-123, 118t-119t, 120, 126, 128, 194, 216, 221, 254-255, 265, 270  
hazard ratios for death in subgroups, 121  
AFI trial, 294  
African Americans, 27, 52, 85  
Age. See also *Elderly patients*; *Young patients*.  
AF prevalence and incidence and, 23-25, 24, 26, 27, 61  
AF risk and, 49, 61  
in CHA2DS2-VASc score, 298t  
in CHADS2 score, 294, 294t  
choice of therapy and, 124, 127, 128, 129t, 133  
degeneration of conduction system and, 270  
hospitalizations for AF, 30  
thromboembolic risk and, 286, 292, 293t  
Aggrastat to Zocor (A to Z) Trial, 95  
AHA/ACC/HRS guidelines (2014), 289  
Albuterol, 57  
Alcohol intake, 56, 73, 320-321  
Aldosterone, 44  
Aldosterone antagonists, 88, 90t, 93  
Allopurinol, 319t  
Ambulatory arrhythmia monitoring, 77, 79-80, 81t  
American College of Cardiology. See *ACC/AHA/ESC Guidelines*.  
American Heart Association. See *ACC/AHA/ESC Guidelines*.  
Amiodarone, 116, 159t, 207t, 216-222  
action mechanisms, 207t, 216, 266  
adverse effects, 207t, 209, 218-219, 267  
clinical studies, 118t-119t, 125, 126, 220-222  
contraindications/cautions, 219-220, 324  
derivative of. See *Dronedarone*.  
dosing, 159t, 207t, 209, 217-218  
low-dose, 212  
drug/device interactions, 159t, 219-220, 264, 267, 318t  
implanted device threshold effects, 199t  
indications for, 159t, 216-222  
cardioversion  
failed electrical, 147, 148t  
pharmacologic, 151, 159t  
pretreatment for, 148t, 149  
repeat electrical, 143, 143t, 146t  
maintenance of NSR, 207t, 216-222  
rate control, 258, 266-267  
initiation of therapy, 213, 215t  
monitoring, 201, 202t-203t, 219  
pharmacokinetics, 216  
safety of, 159t, 198, 199, 201-204, 207t, 209, 212, 218-222  
hypotension, 147  
organ toxicity, 209, 212  
toxicity with long-term use, 127, 200, 209, 212

Amoxicillin, 318t  
Amplatzer Cardiac Plug, 372, 373, 379-381  
Anabolic steroids, 319t  
ANDROMEDA, 227  
Anesthesia, for electrical cardioversion, 135-136  
Angiotensin-converting enzyme inhibitors. See *ACE inhibitors*.  
Angiotensin II, 44  
Angiotensin receptor blockers (ARBs), 88-93, 89, 104  
actions of, 90t  
ANP (atrial natriuretic peptide), 43, 60  
Anti-inflammatory agents, 40, 93, 98, 317, 318t  
Antiarrhythmic drugs (AADs), 193-252  
action mechanisms, 204, 206t-207t  
adverse events, 206t-207t  
agents available, 156t-159t, 206t-207t, 216-248  
amiodarone, 207t, 216-222  
disopyramide, 206t, 246-248  
dofetilide, 207t, 237-241  
dronedarone, 207t, 222-233  
ideal agent, 155-164, 205  
propafenone, 206t, 242-246  
sotalol, 207t, 233-236  
anticoagulation and, 193, 213, 215-216  
atrial selective, 155-164  
benefits of, questions on, 115  
cardioversion and, 150-164  
electrical cardioversion  
failed, 147-148, 148t  
repeat, 145, 145t  
pharmacologic cardioversion, 150-164  
choice of AADs for, 154t  
new (atrial selective) AADs, 155-164  
pretreatment prior to cardioversion, 145, 145t, 148-149  
choice of, 204-212, 206t-207t, 210-211  
algorithm/stepwise approach, 208  
atrial selective agents, 155-164  
available agents, 216-248  
guidelines and recommendations, 205, 208, 210-211  
heart failure patients, 212  
hypertensive patients, 209  
patients with coronary artery disease, 209-210  
patients with no or minimal heart disease, 205-209  
for pharmacologic cardioversion, 152, 153t, 154t, 156t-159t  
classification (Vaughan-Williams), 206t-207t  
clinical trials, 116-124, 118t-119t, 220-248  
combination therapy, 214-215  
dosing, 206t-207t  
booster dosing, 213  
drug interactions, 318t

Antiarrhythmic drugs (AADs) (*continued*)

efficacy, 115-116, 118t-119t, 119t, 194  
goals of therapy, 193  
indications for, 194  
  for rate control, 258, 264, 266-267  
initiation of therapy, 205, 212-214, 278-279  
  hospitalization requirements for, 213, 215t  
  test prior to starting, 77-78  
for maintenance of NSR, 133, 183-252  
  agents available, 206t-207t  
  choice of AAD, 204-223, 206t-207t, 208, 210-211  
  efficacy, 194  
  general principles, 193-200  
  goals of therapy, 193  
  indications for, 194  
  initiation of therapy, 205, 212-214  
  safety considerations, 193, 195-198  
  stepwise approach, 208  
monitoring, 80, 200-204, 202t-203t  
  of initiation phase, 212-214, 215t  
outpatient use of, 213, 215t  
for pharmacologic cardioversion, 154t  
pill-in-the-pocket approach, 151, 213  
pretreatment with, prior to cardioversion, 145, 145t, 148-149  
for rate control, 258, 264, 266-267  
safety considerations, 117-120, 151-152, 194, 195-198  
  AF conversion to atrial flutter, 152  
  atrial proarrhythmias, 197-198  
  atrial remodeling and, 165  
  blood tests/monitoring, 79, 80, 200-204, 202t-203t  
  bradyarrhythmia, 197, 198, 212  
  hemodynamic effects, 199-200  
  implanted device function, 199, 199t  
  mortality, 117-120  
  organ toxicity, 200, 209, 212  
  proarrhythmias, 195-198, 209  
  QT prolongation, 196-197, 198t  
  risk-benefit ratio, 205  
  torsade de pointes (TdP), 195, 196-197, 196, 213  
  toxicity, 115, 127, 129, 151-152, 200, 209  
  ventricular proarrhythmias, 195-197, 196, 212  
  side effects, 195  
  vs catheter ablation, 175-177, 178t-180t, 182-183  
Antibiotics, 198t, 317, 318t  
Anticoagulation therapy, 151, 193, 304-372. See also *Warfarin*.  
  agents available  
    AADs, 193, 213, 215-216  
    apixaban, 339-347  
    dabigatran etexilate, 323-334

Anticoagulation therapy, agents available (*continued*)

  direct thrombin inhibitors, 304, 305, 322-334  
  edoxaban, 334, 347-351  
  factor Xa inhibitors, 304, 305, 334-351  
  rivaroxaban, 335-339  
  warfarin, 304-322, 356t  
  bridging therapy, 369, 370  
with cardioversion procedures, 136-137, 151, 359-363, 366-367  
  AF duration and, 359-363  
  prevention of new thrombus, 363, 364  
  risk of preexisting thrombus, 360-363  
for catheter ablation, 170-171  
with catheter ablation, 171  
chronic, 289  
discontinuance prior to catheter ablation, 171  
duration of treatment with, 121, 124, 129, 134  
long-term continuation of, 121, 129  
newer anticoagulants, 304, 322-357  
  advantages and disadvantages, 356t  
  direct thrombin inhibitors, 304, 305, 322-334  
  factor Xa inhibitors, 304, 334-351  
  summary of, 351-357, 356t  
oral anticoagulants, 304-322  
prophylactic, for cardioversion, 136-137  
special situations  
  AF ablation and Cox-Maze procedure, 364  
  AF due to reversible causes, 368-369  
  AF patients presenting with stroke, 364-365  
  atrial flutter, 365-368  
  cardioversion procedures, 359-363  
  interruption of anticoagulation in AF patients, 369  
  patients with coronary interventions, 369-372  
  warfarin interruption, 370  
for stroke prevention, 170-171  
  efficacy, 116, 120-121  
  risks vs benefits, 289  
  treatment algorithm, 305  
  in treatment algorithm, 305  
  triple therapy, 369-370, 371-372  
Antidepressants, 198t  
Antifungal agents, 198t  
Antihistamines, 198t, 371  
Antihypertensive agents, 61, 305  
Antioxidants, 101  
Antiplatelet therapy, 113, 305, 357-359  
  aspirin, 357-358  
  bleeding risk, 358, 370-372  
  combination of agents, 304, 358-359  
  dosage, 371

Antiplatelet therapy (*continued*)  
 drug interactions, 318t  
 efficacy of, 304

Antithrombotic therapy, 113, 296t, 303-372.  
 See also *Thromboembolism*.  
 ACCP guidelines (2014), 295, 296t

Antithyroid drugs, 319t

Antiviral agents, 198t, 318t

Anxiety, differential diagnosis of, 67t

Aortic plaque, 292

Aortic stenosis, 65, 68

Apixaban, 335, 339-347  
 as alternative to warfarin, 295, 351  
 bleeding risk, 331-334, 333t  
 clinical trials, 339-347, 343t, 344  
 ARISTOTLE, 342-347, 346t, 347, 348t  
 AVERROES, 339-342, 343t, 344  
 in treatment algorithm, 305

Aprindine, 126

ARBs (angiotensin receptor blockers), 88-93, 89, 104, 305  
 in combination with AADs, 214

ARISTOTLE study, 342-347, 346t, 347, 348t

ARMYDA3 trial, 94

Arrhythmias  
 related, 16-17, 17, 48t  
 shock-induced, 134, 149

ASA. See *Aspirin*.

ASAP study, 379

Aspirin, 357-358  
 drug interactions, 317  
 SPAF trials, 357-358  
 stroke hazard rate with, 357  
 for stroke prevention, 296t, 357-358  
 combination therapy, 304, 305, 358-359  
 in treatment algorithm, 305  
 in triple therapy, 369-370, 371-372

Astemizole, 198t

Asymptomatic AF, 31, 65, 69  
 treatment choice and, 129, 129t

Atenolol, 258, 260t, 265, 266

ATHENA trial, 227-229, 230-231

Atherosclerotic plaque, 283

Athletes, 51, 52

Atorvastatin, 94-98, 96t-97t

Atria, electrophysiologic properties of, 155, 160

ATRIA study, 23, 314, 315

Atrial arrhythmias, 48t

Atrial defibrillators, 134, 135t, 140, 149-150

Atrial dilatation, 47, 48t, 53, 284

Atrial electrical abnormalities, 34

Atrial-esophageal fistula, 172, 173t

Atrial fibrillation (AF)  
 classification of, 17-20  
 consequences and prognosis of, 27-31  
 definition of, 13  
 on electrocardiogram (ECG), 15  
 epidemiology, 23-32  
 mechanism of, 33-40, 34  
 monitoring of, 76-80, 81t  
 new-onset, stroke risk in, 300-301, 302  
 pathophysiology of, 33-45, 34  
 perpetuation of ("AF begets AF"), 38-39, 85, 193  
 prevalence and incidence of, 23-26, 24, 25  
 prevention of, 83-108, 84  
 related arrhythmias, 16-17, 17  
 therapeutic approaches, 112-113. See also *Therapy*.  
 triggers of, 17, 33-36, 167  
 variety of clinical presentations in, 65, 69

Atrial fibrosis. See *Fibrosis*.

Atrial flutter, 16-17, 17, 57-58  
 after catheter ablation, 174  
 anticoagulation for, 365-368  
 cardioversion of, 164  
 conversion of AF to, 139, 152  
 electrocardiogram of, 18  
 EPS for, 79

Atrial natriuretic peptide (ANP), 43, 60

Atrial pressure, elevated, 47, 48t

Atrial remodeling, 39, 85-88, 150, 165  
 anti-remodeling therapies, 85-88, 89  
 regression with AADs, 193

Atrial selective AADs, 155-160

Atrial septal defect (ASD), 54

Atrial size/volume, 36, 60, 75

Atrial structural abnormalities, 34

Atrial stunning, 136, 142-143, 284

Atrial systolic function, 142-143

Atrial tachycardia, 16, 17, 17. See also *Tachycardia*.

Autoimmune processes in AF, 38

Autonomic nervous system/tone, 34, 40, 47, 48t, 204

AV junction RV ablation, 118t-119t

AV nodal ablation, 270-272, 277, 279  
 risks and complications of, 271-272

AV nodal agents, 274. See also *Rate control*.

AV nodal block, 277

AV nodal modification, 272

AV nodal vagal stimulation, 273  
 AVERROES trial, 339-342, 343t, 344  
 Azathioprine, 318t

BAATAF, 293, 304  
 BAFTA study, 309  
 Barbiturates, 319t  
 Baylor University Medical Center study, 58-59, 59  
 $\beta$ -Agonists, 54  
 $\beta$ -Blockers, 74, 89, 258-260  
   clinical studies, 117, 118t-119t, 126  
   combination therapy, 274, 275, 278  
     with statins, 95-98  
   contraindications/cautions, 258-260, 275  
   indications for, 56, 128, 152, 205, 209, 258-260  
   for rate control, 255, 258-260, 259t, 260t, 273-274, 278  
 Birmingham scheme of stroke risk, 298, 298t, 300, 309  
 Bleeding risk, 289, 306  
   antiplatelet therapy, 358  
   apixaban, 331-334, 333t  
   dabigatran, 337-339, 340t-341t  
   edoxaban, 350-351, 354t-355t  
   strategies to reduce, 370-372  
   vs stroke prevention, 315  
   warfarin, 306, 313-315, 316, 317, 326-329, 328t

Blood pressure, 61  
   hypertension, 51-52. See also *Hypertension*.  
   hypotension, 65

Blood stasis, thromboembolism and, 284  
 Blood tests, 71, 72t, 76-77, 80  
 Blue toe syndrome, 321  
 BNP. See *Brain natriuretic peptide*.  
 Body mass index (BMI), 55, 61  
 Bosentan, 318t  
 Bradycardia, 149, 198  
 Bradycardia, 142, 152, 197, 198, 212  
   rate-control therapy and, 256-257  
 Brain imaging, 287  
 Brain natriuretic peptide (BNP), 43-44, 60, 79  
 Bypass surgery. See *CABG*.

C-reactive protein (CRP), 38, 60, 95, 98, 285  
 CABANA trial, 177  
 CABG, post-surgery AF and, 48t, 55, 57, 58-59, 59  
   anticoagulation, 368-369, 370  
   case study, 393-395  
   electrical cardioversion and, 141  
   steroid therapy and, 98-101, 100  
 CAFA, 293, 304, 306

Caffeine, 26, 56-57  
 Calcium channel blockers (CCBs), 89, 260-261  
   combination therapy, 265, 266, 274, 275, 278  
   contraindications and cautions, 260, 275  
   for rate control, 128, 152, 255, 260-261, 265, 273-274, 275, 278  
   for repeat cardioversion, 145  
 Calcium loading, 89  
 Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF) scoring system, 73  
 Canadian trials. See *CTAF*; *CTOPP*.  
 Candesartan, 90-91  
 CAPP, 91  
 CARAF I and II studies, 95-98, 245-246  
 Carbamazepine, 319t  
 Cardiac Arrhythmia Suppression Trial, 245  
 Cardiac conditions associated with AF, 48t, 51-54  
 Cardiac murmur, 61  
 Cardiac pacemakers. See *Pacemakers*.  
 Cardiac surgery, post-operative AF and, 40, 57, 58-59, 59  
   electrical cardioversion and, 142  
   steroid therapy and, 98-101, 100  
 Cardiac tamponade, 172-173, 173t  
 Cardiac thromboembolism, 285  
 Cardioembolic stroke, 286-287, 288  
 Cardiomyopathy, tachycardia-induced, 28, 41, 42, 65, 69, 128  
 Cardiovascular disease, 25  
 Cardiovascular drugs, 318t  
 Cardiovascular Health Study (CHS), 23  
 Cardiovascular risk factors for thromboembolism, 293t  
 Cardiovascular side effects of AAD initiation, 212-213  
 Cardioversion, 115, 133-192. See also *Electrical cardioversion*;  
   *Pharmacologic cardioversion*.  
   anticoagulation for, 136-137, 151, 359-363, 366-367  
     prevention of new thrombus, 363, 364  
     risk of preexisting thrombus, 360-363  
   atrial defibrillators, 134, 135t, 140, 149-150  
   checklist for prior to, 134, 135t  
   direct current, 134  
   electrical, 134-151  
     safety of, 151  
   failed, 143-144, 144, 146  
     pharmacologic facilitation of, 147-149, 148t  
   high energy shock, 139, 147t  
   indications for, 134-135, 137, 208, 275, 277  
   internal, 133, 134, 149  
   overview of, 134  
   pharmacologic, 150-164  
     factors to consider, 154, 154t  
     new AADs for, 155-164, 160

Cardioversion, pharmacologic (*continued*)  
   pill-in-the-pocket strategy, 151, 158t, 213  
   recommended AADs for, 154t, 156t-159t  
   pretreatment with AADs prior to, 145, 145t, 148-149  
   repeat, AADs for, 145, 145t, 146t, 147  
   spontaneous, 150  
   TEE-guided, 80, 361-363  
   thromboembolism after, 285, 359-363  
 CARTO, 170  
 Carvedilol, 260t  
 Case studies, 389-399  
   AF patient with stent placement, 397-399  
   AF post-CABG, 393-395  
   AF with hyperthyroidism, 395-397  
   elderly patient with new-onset AF, 391-393  
   lone AF, 389-391  
 CAST, 77, 115, 212, 245  
 Catecholamines, 35  
 Catheter ablation, 133, 164-184  
   adverse events, 176  
   clinical trials, 178t-180t  
   complications, 171-173  
   efficacy and safety, 151, 176-177, 181  
   focal triggers, 165, 166  
   follow-up and recurrence of AF, 173-174  
   indications for, 133-134, 151, 177-184  
   outcomes and further management, 175  
   periprocedural management, 170-171  
     anticoagulation, 170-171  
       imaging, 170  
       TEE, 170, 171  
   repeat procedure, 174  
   safety and efficacy, 176-177, 178t-180t, 181-184, 181  
   success rate, 133  
   techniques and procedures, 166-170, 168  
   vs AADs, 175-177, 178t-180t, 182-183  
   vs antiarrhythmic therapy, 175-177  
 CCBs. See *Calcium channel blockers*.  
 Cephalosporins, 318t  
 Cerebral thromboembolism, 286  
 Cerebrovascular accident (CVA), 65, 69, 172  
 Cesarean section, 322  
 CHA2DS2-VASc, 295, 297, 298-300, 298t  
   compared with CHADS2 score, 299, 299t  
 CHADS2 score, 60, 171, 294-297, 294t, 300  
   compared with CHA2DS2-VASc score, 299, 299t  
   limitations of, 295  
   predictive value of, 295  
 CHARM trial, 90-91  
 CHAS2DS2-VASc score, 298t  
 Chest imaging, 71, 73t, 77  
 Chest pain, 43, 66t-67t  
 Chloroquine, 198t  
 Cholesterol embolization, 321  
 Cholestyramine, 318t  
 Chronic medical conditions, 48t, 54-57  
 Chronic obstructive pulmonary disease (COPD), 54  
 Chronotropic incompetence, 257  
 Cibenzoline, 126  
 Cigarette smoking, 57, 83  
 Cimetidine, 238, 240, 319t  
 Ciprofloxacin, 317  
 Circumferential left atrial ablation, 168, 169-170  
 Cisapride, 198t  
 Clarithromycin, 317, 335  
 Classification of AF, 17-20, 68  
   episodes shorter than 30 seconds, 20  
   first-detected episode, 19  
   lone AF, 20, 47  
   long-standing persistent AF, 19  
   non-valvular AF, 19  
   paroxysmal AF, 19  
   permanent AF, 19  
   persistent AF, 19  
   recurrent episode, 19  
   secondary to other conditions, 20  
 Clinical manifestations, 65-70  
   asymptomatic AF, 31, 65, 69  
   differential diagnosis of chest pain, 66t-67t  
   poor correlation with AF, 68, 78  
   variation in, 65, 69  
 Clonidine, 267-268, 278  
 Clopidogrel, 305, 358-359  
   in combination with aspirin, 305, 358-359, 370-371  
   in combination with irbesartan, 310  
   drug interactions, 317  
 CNs agents, 319t  
 Coagulation. See also *Anticoagulation therapy*.  
   anticoagulation therapy, 151, 193, 304-322  
   hypercoagulable state, 28, 284-285  
 Coffee consumption, 26, 56-57  
 Complications  
   of AF, 65, 69, 84  
   of catheter ablation, 171-173  
   of DC cardioversion, 142-143  
   thromboembolic, 120-121, 143, 285, 288, 290t-291t  
 Computed tomography. See *CT scans*.  
 Conduction block, 35

Congenital heart disease, 54  
 Consequences of AF, 27-31  
   hospitalizations and costs, 29-31, 30  
   impaired hemodynamics, 28-29  
   mortality, 27, 29  
   quality of life, reduced, 27, 31  
   thromboembolism, 27-28  
 COPD (chronic obstructive pulmonary disease), 54  
 Copenhagen Stroke Study, 28  
 COPPA II, 246  
 Coronary artery bypass graft. See *CABG*.  
 Coronary artery disease (CAD), 47, 53, 66t  
   AADs for, 209-212  
 Coronary blood flow, impaired, 43  
 Coronary interventions, anticoagulation for, 369-372  
 Coronary stents, 371-372  
 Corticosteroids. See *Glucocorticosteroids*.  
 Cost-effectiveness of treatment, 124  
 Costs of AF, 29-31  
 Cox, James, 184  
 Cox-Maze procedure, 184-187, 185. See also *Surgical ablation*.  
 COX-2 inhibitors, 317, 318t  
 CRAFT, 161  
 Creatinine, serum, 223  
 CRRAFT, 127  
 CT scans, 77, 170  
 CTAF, 122, 221, 222, 235-236, 245  
 CTOPP, 103  
 CYP systems, 161, 316  
  
 Dabigatran etexilate, 323-334  
   as alternative to warfarin, 295, 351  
   bleeding and, 337-339, 340t-341t  
   characteristics, 323-325  
   clinical trials, 325-331  
   contraindications and cautions, 324  
   dosing/interactions, 324  
   efficacy and safety, 324-331  
   FDA approval of, 323  
   RE-LY trial, 325-330, 326, 327t  
   RELY-ABLE trial, 330-331  
   risk category and, 296t  
   switching to and from, 324-325  
   in treatment algorithm, 305  
 DAFNE, 225-226  
 Danish Diet, Cancer, and Health Study, 57, 102  
 DC cardioversion, 134  
 Decongestants, 74  
 Defibrillation, atrial, 134, 135t, 140, 149-150  
  
 Defibrillators, 141, 149-150  
   dual-chamber, 149-150  
   memory function of, 81t  
 Definition of AF, 13  
 Demographics of AF, 27  
 Device-based therapy, 103-104, 113. See also *Pacemakers*.  
 Device interactions. See *specific agents*.  
 Dexamethasone, 99  
 Diabetes, 20  
   in CHA2DS2-VASc score, 298t  
   in CHADS2 score, 294, 294t  
 Diagnosis of AF. See also *Classification of AF; Evaluation of patient with AF*  
   characterization of episodes, 17-19  
   clinical manifestations, 65-70  
   differential diagnosis, 16, 66t-67t  
   electrocardiogram (ECG) in, 14-16  
   pacemakers and, 16  
   patient evaluation, 71-82  
   testing, 72t-73t  
 Diagnosis of thromboembolic stroke, 287  
 DIAMOND trial, 29, 122, 212, 240-241  
 Diaphragmatic paralysis, 172  
 Dicloxacillin, 318t  
 Diet, 320-321  
   low-salt, 83  
 DIG study, 29  
 Digitalis, 29, 118t-119t, 126, 205, 220, 275  
 Digoxin, 74, 261-264, 264t  
   action mechanism, 261  
   AF resulting from, 54  
   clinical studies, 117, 126  
   combination therapy, 265, 266, 275, 278  
   contraindications/cautions, 154, 263-264  
   dosing, 263, 264t  
   drug interactions, 219-220, 261, 267  
   exercise stress testing and, 77-78  
   indications for, 261-263  
     for rate control, 255, 261-264, 264t, 274-275, 278  
   IV, 274-275  
 Diltiazem, 205, 260, 262t, 274  
   cautions for, 260  
   clinical studies, 118t-119t, 127  
   combination therapy, 265, 266, 278  
   drug interactions, 261  
 DIONYSOS study, 229  
 Direct thrombin inhibitors, 304, 305, 322-334  
   action mechanism, 322  
   dabigatran, 323-334

- Disopyramide, 206t, 246-248  
 action mechanism, 246  
 adverse effects, 247  
 clinical studies, 118t-119t, 247-248  
 contraindications, 247  
 dosing, 206t, 246-247  
 drug interactions, 247  
 implanted device threshold effects, 199t  
 in maintenance of sinus rhythm, 246  
 monitoring, 202t-203t  
 pharmacokinetics, 246  
 safety, 199, 206t
- Disulfiram, 319t
- Dobutamine, 57
- Dofetilide, 157t, 207t, 237-241  
 action mechanism, 207t, 237  
 adverse effects, 157t, 207t, 209  
 clinical studies  
 DIAMOND, 29, 122, 212, 240-241  
 EMERALD, 240  
 SAFFIRE-D, 157t, 240  
 contraindications/cautions, 137t, 238  
 dosing, 157t, 207t, 238  
 drug interactions, 238-239  
 implanted device threshold effects, 199t  
 indications for, 157t, 237-241  
 maintenance of NSR, 207t, 212, 237, 240-241  
 initiation of therapy, 213, 215t, 239  
 monitoring, 200-201, 202t-203t  
 pharmacokinetics, 237  
 safety of, 157t, 199, 200, 207t, 209-212, 238-240  
 success rate for cardioversion, 157t
- Domperidone, 198t
- Dronedaronone, 207t, 222-233  
 action mechanism, 207t, 222-224  
 adverse effects, 207t, 224, 229-232  
 clinical studies, 225-233  
 ADONIS, 226, 229  
 ANDROMEDA, 227  
 ATHENA, 227-229, 230-231  
 DAFNE, 225-226  
 DIONYSOS, 229  
 ERATO, 227  
 EURIDIS, 226, 229  
 PALLAS, 232-233  
 contraindications/cautions, 222, 224-225  
 dosing, 207t, 224  
 drug interactions, 225, 264  
 implanted device threshold effects, 199t
- Dronedaronone (*continued*)  
 indications for, 205-209, 210, 222-223  
 maintenance of NSR, 205-209, 207t, 210, 212, 222-233  
 rate control, 258  
 initiation of therapy, 213, 215t, 222  
 monitoring, 201, 202t-203t  
 pharmacokinetics, 222-223  
 safety of, 197, 198, 199-200, 207t, 212, 222  
 PALLAS study, 232-233  
 stroke risk, 229, 232
- Droperidol, 198t
- Drug interactions. See *specific agents*.
- Dual-chamber defibrillators, 149-150
- Dual-chamber pacemakers, 269, 270-271
- Dyspnea, 68, 69
- Echocardiography, 75-76, 203t, 204  
 risk assessment with, 59-60  
 stroke risk assessment with, 301-303, 303t  
 transesophageal (TEE), 71, 73t  
 transthoracic (TTE), 71, 72t, 75-76
- Edoxaban, 334, 347-351  
 bleeding risk, 350-351, 354t-355t  
 clinical trials, 347-351, 350  
 ENGAGE AF-TIMI 47, 347-351, 350  
 in treatment algorithm, 305
- EHRA scoring system, 73, 74t
- Elderly patients. See also *Age*.  
 amiodarone cautions for, 212  
 case study, 391-393  
 choice of therapy for, 124, 129, 129t  
 degeneration of conduction system in, 270  
 digoxin cautions for, 264  
 hospitalizations in, 29, 30  
 hypothyroidism in, 76  
 lifetime risk and, 26  
 neurologic evaluation, 78  
 prevalence/incidence of AF in, 23-25, 24  
 rate-control strategy in, 124, 129, 129t, 261, 274t
- Electrical cardioversion, 134-150. See also *Cardioversion*.  
 checklist for prior to, 134, 135t  
 complications of, 142-143  
 DC cardioversion, 134, 135t  
 efficacy of, 133  
 failure of, 143-144, 144, 146  
 pharmacologic facilitation of, 147-149, 148t  
 indications for, 133-134, 150-151  
 in monitoring of AADs, 202t, 204



Electrical cardioversion (*continued*)  
outcomes and further management, 143-150  
failed cardioversion, 143-144, 144, 146  
    pharmacologic facilitation of, 147-149, 148t  
recurrence of AF, 143-144, 144  
repeat cardioversion, 135, 145, 147, 147t  
    AADs facilitating, 143, 143t  
    restoration of NSR, 143-144  
practical and technical aspects, 135-139  
    anesthesia, 135-136  
    anticoagulation, 136-137  
    energy delivered, 139  
    high energy shock, 139, 147t  
    life-support capabilities, 135-136  
    pads/paddle use, 137, 138, 141  
    shock-induced arrhythmias, 149  
    shock synchronization, 137-139  
    shock waveforms, 139, 140  
    special populations, 141-142  
        acute MI, 141  
        hyperthyroidism, 141-142  
        patients with implanted device, 141  
        post-cardiac surgery, 141  
        pregnancy, 142  
    success rate, 134  
Electrical remodeling, 88, 150, 165  
Electrocardiogram (ECG), 13-16, 15, 75  
    in AAD monitoring, 201, 202t  
    ambulatory recordings/monitoring, 77, 79-80, 81t  
    of atrial flutter, 18  
    changes following cardioversion, 142  
     $\delta$  wave on, 78  
    dilemma in diagnosis of AF, 14-16  
    of fibrillation, 15  
    follow-up monitoring, 78-80  
    in patient evaluation, 71, 72t, 75-76  
    risk assessment with, 59-60  
Electrodes, placement for cardioversion, 137, 138, 141  
Electrolyte testing, 77, 79, 80, 202t  
Electrophysiology study (EPS), 71, 73t, 78, 79  
Embolism. See *Thromboembolism*.  
EMERALD trial, 240  
Enalapril, 89-90  
Endothelial and endocardial abnormalities, 283  
Endurance sports exercise, 51, 52, 85, 123, 322  
ENGAGE AF-TIMI 47, 347-351, 350  
Epidemiology of AF, 23-32  
    consequences and prognosis, 27-31  
    demographics, 27

Epidemiology of AF (*continued*)  
    increase in AF, 23, 24  
    lifetime risk, 26  
    prevalence and incidence, 23-26, 24, 25  
    risk factors, 26  
EPOCH study, 52  
ERAFT, 245  
ERATO study, 227  
Erythromycin, 335  
ESC Guidelines. See *ACC/AHA/ESC Guidelines*.  
Esmolol, 259t, 274  
Ethnicity. See *Race/ethnicity*.  
Etiology of AF, 47, 48t, 62. See also *Risk factors*.  
Etomidate, 136  
EURIDIS, 226, 229  
Euro Heart Survey for AF, 299  
EuroHeart Failure Survey, 29  
European Heart Rhythm Association (EHRA) scoring system, 73, 74t  
European Society of Cardiology. See *ACC/AHA/ESC Guidelines*.  
Evaluation of patient with AF, 65, 71-82, 273  
    follow-up encounters, 78-80  
    minimum evaluation, 72t  
    monitoring strategies, 81t  
    new-onset evaluation, 71-78, 72t-73t, 80  
        blood tests, 76-77, 80  
        chest imaging, 77  
        echocardiogram, 75-76  
        electrocardiogram, 72t, 75-76, 80  
        electrophysiology study, 71, 73t, 78  
        exercise stress testing, 72t, 77-78, 80  
        history, 65, 71-74, 72t, 80  
        physical examination, 65, 74-75  
        symptom scoring systems, 73, 74t  
Exercise, 85, 104  
    AF risk and, 52, 85, 86t-87t  
    exercise tolerance, treatment of AF and, 123, 123  
    stress testing, 71, 72t, 77-78, 80, 203t, 204, 277-278  
    walking, 85, 86t-87t  
Extracellular matrix (ECM), 38-39, 85, 283, 285  
  
F (fibrillatory) waves, 14  
Factor Xa inhibitors, 304, 305, 334-351  
    apixaban, 335, 339-347  
    characteristics, 334-335  
    edoxaban, 334, 347-351  
    indications for, 334-335  
    rivaroxaban, 335-339  
Family history of AF, 47, 73  
Fatigue, 68, 69

N-3 Fatty acids, 102  
 Fentanyl, 136  
 Fibrates, 318t  
 Fibrosis, 36, 39, 49, 85, 88, 212  
 First-detected episode, 19  
 Fish oil, 89, 102, 318t  
 Flecainide, 158t  
   adverse effects, 158t  
   clinical studies, 118t-119t, 125  
   dosing, 158t  
   drug interactions, 158t  
   implanted device threshold effects, 199t  
   indications for, 158t, 205-209, 206t, 210  
     pharmacologic cardioversion, 152-153  
     repeat electrical cardioversion, 143, 143t  
   monitoring, 202t-203t  
   safety, 198, 199, 200  
   success rate, 158t  
 Fluconazole, 318t  
 Fluorouracil, 319t  
 Fluvastatin, 319t  
 Focal activation, 33-36, 37, 165, 166  
 Foci/sites of initiation, 33-36, 37  
 Follow-up evaluation, 78-80  
 Fondaparinux, 322  
 Framingham risk score, 60, 61, 300, 302  
 Framingham Study, 23, 26, 28, 29, 52, 56, 60  
  
 Gender  
   AF incidence and prevalence and, 24, 25, 27  
   in CHA2DS2-VASc score, 298t  
   thromboembolic risk and, 292, 293t, 298t  
 Gene therapy, 273  
 Genetic AF, 49-51, 62  
   genetic etiology, evidence for, 47  
   genetic polymorphisms, 315-316  
   genetic variants, 34  
   susceptible phenotypes, 85  
 GI agents, 319t  
 GISSI-AF trial, 93  
 Glucocorticosteroids, 89, 90t, 98-101, 100, 104  
   safety of, 101  
 Goals of therapy, 109-114, 110  
 Griseofulvin, 318t  
 Growth factors, 88, 285  
  
 Haloperidol, 198t, 319t  
 HAS-BLED scoring system, 314-315  
 Heart disease  
   AF and, 27, 47, 53  
   statins and, 92  
   valvular, 53  
 Heart failure (HF), 28-29, 52-53, 61, 69  
   AAD therapy and, 194, 212  
   AF with, 122, 126-127, 271  
     AF-CHF trial, 122, 126-127  
   decompensated, 65, 275  
   pacemaker implantation, 271  
 Heart rate, 14, 16, 254, 258t. See also *Rate vs rhythm control*.  
   chronotropic incompetence, 257  
   with exercise, 258t  
   outpatient monitoring, 78  
   rapid, 41  
   with rate-control therapy, 254, 255, 258t  
     lower limit, 257, 258t  
     target (goal), 117, 254  
     upper limit, 258t  
 Heart sounds, 74  
 Hematocrit, elevated, 284  
 Hematuria, 314  
 Hemodynamic effects of AF, 28-29, 41-44  
   impaired coronary blood flow, 43  
   irregular ventricular rate, 41-43  
   loss of atrial contraction, 43  
   neurohormonal activation, 43-44  
   rapid heart rate, 41  
 Hemodynamic stability, achieving, 110  
 Hemodynamically unstable patients, rhythm control for, 137  
 HEMORR2HAGES risk index, 314, 315  
 Heparins, 362, 365  
   cardioversion and, 137, 171, 362  
 Herbal supplements, 320, 320t  
 Hispanics, 85  
 History, 65, 71-74, 72t, 80  
 HIV protease inhibitors, 198t  
 HMG-CoA Reductase Inhibitors (statins), 89, 90t, 93-98  
 Holter monitoring, 71, 73t, 81t  
 Hospitalizations for AF, 29-31, 30, 123, 127  
   in hospital telemetry, 81t  
 HOT CAFE trial, 116, 118t-119t, 122  
 HRS/EHRA/ECAS Consensus Statement, 174, 177, 295  
 Hydrocortisone, 99, 100  
 Hypercoagulable state, 28, 284-285

- Hypertension, 51-52, 209  
 ACE inhibitors and, 92, 214  
 antihypertensive agents, 61, 305  
 in CHA2DS2-VASc score, 298t  
 in CHADS2 score, 294, 294t  
 clonidine for, 267-268, 278  
 treatment for, 61
- Hyperthyroidism, 55-56, 141-142, 368-369  
 case study, 395-397
- Hypertrophic cardiomyopathy (HCM), 54, 65, 68
- Hypotension, 65, 74, 147
- Hypothyroidism, 76
- Ibutilide, 145t, 148-149, 156t, 164  
 implanted device threshold effects, 199t  
 indications for, 161  
   cardioversion of atrial flutter, 164  
   failed electrical cardioversion, 147-148, 148t  
   pharmacologic cardioversion, 148t, 156t  
   repeat electrical cardioversion, 143, 143t  
 monitoring, 149  
 safety of, 148-149, 156t, 161-164  
 torsade de pointes (TdP), 148, 155, 156t
- Idiopathic AF, 47-51, 48t
- IKur, 155
- Imaging, 170, 287
- Immediate recurrence of AF (IRAF), 144-146, 145t
- Implanted devices. See also *Pacemakers*.  
 electrical cardioversion and, 141  
 interference from AADs, 199, 199t  
 threshold effects of AADs, 199t
- Incidence of AF, 23, 24
- Individualized approach to therapy, 109, 110, 111, 115, 126, 129, 129t, 203
- Inflammation, 26, 36-38, 40, 48t, 60, 93. See also *Anti-inflammatory agents*.  
 AF prevention and, 89  
 anti-inflammatory agents, 40, 93, 98  
 thromboembolic risk and, 285
- Initiating event, 33-36, 35
- Inpatient settings (AADs), 152-153
- Interferon, 318t
- Internal cardioversion, 133, 134, 149
- Ion currents, 160-161, 160
- Irbesartan, 320
- Isoniazid, 318t
- Isoproterenol, 40
- J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation), 125-126
- Joules, 139
- Ketoconazole, 198t, 238-240, 324, 335
- Laboratory data, 60
- Lactation, 322
- Left atrial appendage (LAA)  
 blood stasis and, 284  
 closure devices, 372-375, 373, 374  
 as source of thromboembolism, 286  
 surgical amputation/ligation, 381
- Left atrial dilatation. See *Atrial dilatation*.
- Left atrial pressure, elevated, 47, 48t
- Left atrial vein ablation, 168, 169-170
- Left atrium. See also *Atria*.  
 reservoir function, 38, 60  
 size/volume, 38, 60, 75
- Left ventricular dilatation, 284
- Left ventricular dysfunction, 28-29, 88
- Left ventricular ejection fraction (LVEF), 41
- Left ventricular end diastolic pressure (LVEDP), 43
- Left ventricular hypertrophy (LVH), 52, 209
- Life-support capabilities, 135-136
- LIFE trial, 91
- Lifestyle modifications, 83-85
- Limb ischemia, 290t
- Liver function tests, 72t, 77, 201, 202t
- Liver toxicity, 200
- LMWH, 137, 362, 363, 368, 370. See also *Heparins*.
- Lone AF, 20, 47-49, 205  
 case study, 389-391
- Long-standing persistent AF, 19
- Loop diuretics, 198t
- Loop recorders, 81t
- Losartan, 91
- Macrolides, 198t, 318t
- Magnesium level assessment, 200, 202t
- Magnesium sulfate, 268
- Manitoba study, 29
- Mechanism of AF, 33-40, 34  
 "AF begets AF," 38-39, 85, 193  
 arrhythmia substrate, 36-38, 165  
 focal activation vs multiple wavelets, 36, 37  
 initiating event, 33-36, 35  
 modulating factors, 35, 40  
 multiple-source hypothesis, 36, 37  
 single-focus theory, 33-36, 37

Medical conditions associated with AF, 48t, 54-57  
 Medication history, 54  
 Medications, AF and, 57  
 Mefloquine, 198t  
 Megestrol, 238  
 Mesalamine, 318t  
 Mesenteric ischemia, 290t  
 Metabolic risk factors for thromboembolism, 293t  
 Metabolic syndrome, 55  
 Methadone, 198t  
 Methylprednisolone, 98, 99-101  
 Metoprolol, 259t, 274  
 Metronidazole, 317, 318t  
 Midazolam, 136  
 Milrinone, 57  
 Mitral stenosis, 284  
   anticoagulation with, 297  
 Monitoring of AADs, 80, 200-204, 202t-203t  
 Monitoring of AF, 76-80  
   recording options, 81t  
 Mortality, 27, 29, 115-116, 117-120  
   catheter ablation and, 173, 173t  
   hazard ratios for death in subgroups, 121  
   stroke and, 285, 288  
 MOST, 103  
 MRI, 170, 287  
 Multifocal atrial tachycardia (MAT), 16, 54  
 Multiple-source hypothesis, 36, 37  
 Myocardial infarction (MI)  
   AADs and, 115, 209  
   acute, 53  
     DC cardioversion and, 141, 151  
     transient AF during, 58  
   AF secondary to, 20, 47, 48t, 53  
   precipitated by AF, 68  
   transient AF and, 58  
 Myocardial necrosis, 142  
  
*N*-acetylcysteine (NAC), 101  
*N*-3 Polyunsaturated fatty acids (PUFAs), 102  
 NAC (*N*-acetylcysteine), 101  
 Nadolol, 258  
 Nafcillin, 318t  
 NASPE Registry, 271  
 NavX, 170  
 Neurohormonal activation, 43-44  
 Neurologic evaluation, 78  
 Niiigata Preventive Medicine Study, 55  
 Nitrous oxide, 284

Non-valvular AF, 19  
 Nondihydropyridine CCBs. See *Calcium channel blockers*.  
 Nonpharmacologic therapy. See also *Implanted devices*; *Surgical ablation*.  
   for prevention of AF, 83-85, 84  
   for rate control, 269-273, 269t  
   for stroke prevention, 372-381  
 Norepinephrine, 44  
 Normal sinus rhythm (NSR), 133-252. See also *Antiarrhythmic drugs (AADs)*.  
   anticoagulation and, 134  
   maintenance of, as a goal, 193  
     AADs for, 193-252, 206t-207t, 210-211, 216-248  
     indications for, 194  
   restoration of, as a goal, 109, 115, 124, 129  
   restoration and maintenance of, 133-252  
     AADs for, 150-164, 193-200  
     catheter ablation, 133, 151-153  
     electrical cardioversion, 133, 134-150  
     pharmacologic cardioversion, 150-164  
     quality of life and, 122  
     stroke and, 115, 121  
     success rates, 144-145  
 NSAIDs, 317, 318t  
  
 Obesity, 55, 61  
 Obstructive sleep apnea, 55  
 Ocular effects, 219  
 Offset pause, 65, 69  
 Omeprazole, 371  
 ONTARGET trial, 92  
 Oral contraceptives, 319t  
 Organ toxicity, 200, 209, 212  
 Outpatient settings (for AADs), 152-153  
 Oxygen  
   antioxidants, 101  
   oxidative stress, 101  
   reactive oxygen species, 88, 89, 93  
  
 P-glycoprotein inducers, 324  
 P waves, 13, 59-60  
 Pacemakers, 269-272, 279  
   ACC/AHA/HRS device guidelines, 103-104  
   AF diagnosis and, 16  
   AF prevention and, 103-104  
   choice/types of, 270-271  
   dual-chamber, 269, 270-271  
   physiologic pacing with, 104  
   single-chamber, 269-270

Pads/paddles, placement for cardioversion, 137, 138, 141  
 PAF/PAF-2 trials, 124-125  
 PAI-1, 284  
 Pain, electrical shock and, 136  
 PALLAS study, 232-233  
 Parasympathetic nervous system, 40, 48t  
 Paroxysmal AF, 19, 38, 40, 165  
   antithrombotic therapy in, 295  
   clinical trials, 124-126  
   and heart failure, 122  
   rate vs rhythm control in, 128, 129t  
   vs persistent AF, 167  
 Pathophysiology of AF, 33-45, 34, 165. See also *Risk factors*.  
   hemodynamic effects, 41-44  
     impaired coronary blood flow, 43  
     irregular ventricular rate, 41-43  
     loss of atrial contraction, 43  
     neurohormonal activation, 43-44  
     rapid heart rate, 41  
   mechanism of AF, 33-40, 34  
     "AF begets AF," 38-39, 85, 193  
     arrhythmia substrate, 36-38, 165  
     inflammation and, 36-38, 48t  
     initiating event, 33-36, 35  
     modulating factors, 40  
 Patient evaluation. See *Evaluation of patient with AF*.  
 PAVE study, 271  
 Pentamidine, 198t  
 Percutaneous closure of LAA, 372-375, 373, 374  
 Pericarditis, 48t, 53-54, 67t  
 Peripheral thromboembolism, 28, 285, 288  
 Permanent AF, 19  
 Persistent AF, 19  
   vs paroxysmal AF, 167  
 Pharmacologic agents for rate control, 257-264  
 Pharmacologic cardioversion, 150-164. See also *Cardioversion*.  
   choice of AADs for, 154t  
   new (atrial selective) AADs, 155-164  
   indications for, 150-151  
   pill-in-the-pocket strategy, 151, 158t, 213  
   safety of, 151-153  
     anticoagulation, 151  
     inpatient vs outpatient settings, 152-153  
     toxicity of AADs, 151-152  
   success rate, 144-145, 150  
 Pharmacologic prevention of AF, 85-102. See also *Prevention of AF*.  
   modes of action, 90t  
 Pharmacologic prevention of stroke in AF, 303-372  
 Phenothiazines, 198t  
 Phenytoin, 319t  
 Physical examination, 65, 74-75  
 Physical exercise, 85, 86t-87t, 104, 123  
 PIAF trial, 116, 118t-119t  
 Pill-in-the-pocket strategy, 151, 158t, 213  
 Pilsicamide, 125-126  
 PLAATO, 372, 373  
 Platelet activation, 284-285  
 Platelet count, 76  
 Platelet-derived growth factor (PDGF), 88  
 Platelet factor 4, 284-285  
 Pneumonia, 67t, 173t  
 Polyunsaturated fatty acids (PUFAs), 102  
 Postoperative AF, 48t, 57, 58-59, 59  
   anticoagulation for, 368-369  
   case study, 393-395  
   fish oil and, 102  
   pericarditis and, 53  
   steroid therapy and, 98-101, 100, 104  
 Potassium channels, 49, 207t  
 Potassium level assessment, 200, 202t  
 PR interval, 59, 61  
 Prasugrel, 371  
 Pravastatin, 95, 96t-97t  
 Pre-excitation syndrome, 16, 57, 68, 275, 277  
 Pregnancy  
   DC cardioversion in, 142  
   warfarin use in, 321-322  
 PREVAIL trial, 377-378  
 Prevalence of AF, 23-26, 25  
 Prevention of AF, 83-108, 84  
   device-based therapy in, 103-104  
   goals of, 83, 84  
   nonpharmacologic methods, 83-85, 112  
   pharmacologic, 85-102, 89, 112  
     AADs and, 214-215  
     ACE inhibitors/ARBs, 88-93, 90t, 104  
     aldosterone antagonists, 88, 90t, 93  
     antioxidants, 101  
     fish oil, 102  
     glucocorticosteroids, 89, 90t, 98-101, 100, 104  
     modes of action, 90t  
     RAAS blockade, 88-93, 104  
     statins, 90t, 93-98, 104  
     target pathways, 89  
   recurrence prevention, 205  
   target pathways, 84, 89

Prevention of thromboembolism, 279-352, 283-388.

See also *Thromboembolism, preventive therapies*.

pharmacologic prevention in AF, 303-372, 305

Proarrhythmias, 195-198

atrial, 197-198

ventricular, 195-197, 196, 212

Procainamide, 148t, 154, 200

Prochlorperazine, 238

Prognosis of AF, 27-31

Propafenone, 158t, 206t, 242-246

action mechanism, 206t, 242, 267

adverse effects, 206t, 243

clinical studies, 118t-119t, 125, 244-245

contraindications/cautions, 209, 212, 244

dosing, 158t, 206t, 243

drug interactions, 158t, 244, 261, 264, 318t

implanted devices and, 199t

indications for, 158t, 205-209, 210, 242-246

maintenance of NSR, 206t, 242

pharmacologic cardioversion, 158t

pill-in-the-pocket approach, 151, 158t

pretreatment for pharmacologic cardioversion, 148, 148t

for rate control, 267

repeat electrical cardioversion, 143, 143t, 146t

monitoring, 202t-203t

outpatient use of, 152

pharmacokinetics, 242

safety, 198, 199, 200

Propofol, 136

Propranolol, 274

Protease inhibitors, 198t

PROTECT-AF, 375-376, 377, 378

Prothrombic state, 284-285

Prothrombin time, 76, 313

Prothrombotic plasminogen activator inhibitor 1 (PAI-1), 284

PROVE IT-TIMI 22, 95

Psychosocial factors, 26

Psychotropic drugs, 198t

PUFAs, 102

Pulmonary disease, 54-55

Pulmonary embolus (PE), 54, 67t

chest CT for, 77

Pulmonary vascular and pulmonary disease, 54-55

Pulmonary vein isolation, 38, 168-169, 168

Pulmonary vein stenosis, 171-172

Pulmonary veins (PVs), in paroxysmal AF, 33-34

Purple toe syndrome, 321

QRS complex, 75, 139, 201-204

irregular, 14

narrow, 14

wide, 73t, 78

QT intervals, 60, 75, 78

prolonged, 60, 154, 155, 196-197, 196, 198t, 224

congenital long-QT syndrome, 197

drugs associated with, 198t, 213

Quality of life (QoL), 27, 31, 109, 122, 124, 127

Quinidine, 146t, 200, 324

drug interactions, 264

Quinolones, 198t, 318t

R-R interval, 14, 75

RAAS (renin-angiotensin-aldosterone system) activation, 34

fibrosis and, 88

RAAS (renin-angiotensin-aldosterone system) blockade, 88-93, 89, 104

Race/ethnicity, 27, 52, 85

RACE trial, 116, 118t-119t, 121, 122, 216, 254

RACE II, 255-256

Radiofrequency ablation, 187-188, 270

Ramipril, 92

Ranolazine, 198t

Rate control, 115, 133-192, 253-282. See also *Heart rate*.

in AF, 269-273

algorithms based on clinical presentation, 273-279, 276-277, 280

acute pharmacologic rate control, 273-275, 276-277

chronic pharmacologic rate control, 277-279, 280

decompensated heart failure (HF), 65, 275

sick sinus syndrome or AV block, 277

special populations, acute rate control in, 275-277

Wolff-Parkinson-White (WPW) syndrome, 275-277

bradycardia and, 149, 256-257

caution in, 274-275, 274t

choice of, vs rhythm control, 127-129, 129t

clinical benefit of, 271

clinical trials on, 116-124, 118t-119t

pharmacologic agents used, 116-117

combination therapy, 215, 275

cost-effectiveness of treatment, 124

effectiveness of, 127-128

goals and definitions in, 253-257, 254t

indications for, 128-129, 129t, 208, 253, 254

acute presentation, 254t, 262t, 264t

cautions, 274-275, 274t

chronic presentation, 254t, 262t, 264t

patient characteristics, 129t

lenient, vs strict, 255-256

## Rate control (*continued*)

- nonpharmacologic therapy for, 269-273, 269t
  - AV nodal ablation with pacemaker implantation, 270-272, 277, 279
  - AV nodal modification, 272
  - chronic atrioventricular nodal vagal stimulation, 273
  - gene therapy, 273
  - pacemaker implantation, 269-270
  - regularization of ventricular response with pacing, 272-273
- pharmacologic agents for, 255, 257-264, 273-275
  - acute control with, 254t, 262t, 264t, 274, 275-277, 276-277
  - antiarrhythmic drugs, 258, 264, 266-267
    - amiodarone, 258, 266-267
    - propafenone, 267
    - sotalol, 267
  - β-blockers, 255, 258-260, 259t, 260t, 265, 273-274, 278
  - cautions in titration of therapy, 274t
  - CCBs, 255, 260-261, 265, 273-274, 278
  - chronic control with, 254t, 262t, 264t, 277-279, 280
  - combination therapy, 274, 275
  - comparative studies, 265, 266
  - digoxin, 255, 261-264, 264t, 278
  - diltiazem, 260, 262t
  - other agents
    - clonidine, 267-268
    - magnesium sulfate, 268
    - verapamil, 260-261, 262t
  - strategies for, 253-282
  - target heart rate, 117, 254
  - vs rhythm control. See also *Rate vs rhythm control*.
    - therapy, 115-131, 118t-119t
- Rate vs rhythm control, 115-131, 118t-119t, 253
  - age and, 124, 129t
  - choice of strategy, 112, 124, 127-129, 129t
  - clinical trials: agents used, 116-117, 118t-119t, 125-126
  - clinical trials: outcomes, 116-124, 118t-119t
    - cost-effectiveness, 124
    - CV mortality, 120, 120
    - exercise tolerance, 123, 123
    - heart failure, impact on, 122
    - hospitalization, 123
    - symptoms and QoL, 31, 122
    - thromboembolic complications, 120-121
    - total mortality, 117-120
  - clinical trials: overview, 116-117, 118t-119t
  - clinical trials: specific populations, 124-127
    - AF and heart failure, 126-127
    - symptomatic, paroxysmal AF, 124-126
    - young patients with AF and valvular heart disease, 127

## Rate vs rhythm control (*continued*)

- goals of, 115, 128-129, 129t
  - normal sinus rhythm, 115, 128-129
  - patient characteristics and, 129t
  - safety and efficacy, 115-116, 119t
  - stroke rates and, 292
  - thromboembolism risk, 292
- Reactive oxygen species, 88, 89, 93
- Recurrence of AF, 19, 173-174
  - AADs in prevention of, 205, 213
    - booster dosing, 213
  - catheter ablation and, 173-174
  - electrical cardioversion and, 143-146, 144
    - immediate recurrence (IRAF), 144-146, 145t
- RE-LY trial, 325-330, 326, 327t
- RELY-ABLE trial, 330-331
- Remodeling. See *Atrial remodeling*.
- Renal function tests, 72t, 77, 200, 202t
- Renal thromboembolism, 291t
- Renin-angiotensin-aldosterone system. See *RAAS*.
- Retroperitoneal hemorrhage, 314
- Rheumatic heart disease (RHD), 53, 127
- Rhythm control, 115, 133-252. See also *Antiarrhythmic drugs*;  
*Normal sinus rhythm*; *specific topics*.
  - antiarrhythmic drugs (AADs) for, 193-252
  - anticoagulation therapy and, 215-216
  - catheter ablation, 164-184
  - choice of, vs rate control, 127-129, 129t
  - clinical trials on, 118t-119t
  - electrical cardioversion, 134-150
  - hospitalizations and, 127
  - indications for, 126, 128-129, 129t, 133, 194, 275
    - in hemodynamically unstable patients, 137
    - patient characteristics, 129t
  - maintenance of normal sinus rhythm, 193-252
  - pharmacologic agents for, 116-117
  - pharmacologic cardioversion, 150-164
  - quality of life and, 31
  - vs rate control, 115-131, 118t-119t. See also *Rate vs rhythm control*.
- RIETE score, 314
- Rifampin (rifampicin), 318t, 335
- Right ventricular (RV) pacing, 103
- RIKS-HIA, 263
- Risk assessment, 59-60, 61
  - for stroke, 289-303
- Risk factors, 25-26, 47-64, 48t, 83
  - and AF prevention, targets for, 84
  - assessment with ancillary studies, 59-60, 61
  - cardiac/noncardiac conditions associated with AF, 48t, 51-58, 62

Risk factors (*continued*)

- alcohol and other toxins, 56-57
- cardiac surgery, 57, 58-59, 59
- congenital heart disease, 54
- coronary artery disease and acute MI, 53
- heart failure, 52-53
- hypertension, 51-52
- hyperthyroidism, 55-56
- hypertrophic cardiomyopathy, 54
- medications, 57
- metabolic syndrome, 55
- obesity, 55, 61
- pericarditis, 53-54
- pulmonary vascular and pulmonary disease, 54-55
- supraventricular arrhythmias, other, 57-58
- valvular heart disease, 53
- CV risk and, 85
- idiopathic AF, physiologic, and genetic factors, 47-51
  - aging, 49, 61
  - endurance sports exercise, 51, 52
  - genetic AF, 49-51, 62
  - lone AF, 47-49
- lifetime risk, 26
- prevalence of AF and, 26
- reversible risk factors, controversies on, 58-59
- risk score assessment/algorithm, 59-60, 61
  - for stroke, 120-121, 289-303
- Risk score, 59-60, 61
- Risperidone, 198t
- Ritonavir, 198t, 335
- Rivaroxaban, 335-339
  - action mechanism, 335
  - as alternative to warfarin, 351
  - clinical trials, 336-339
    - ROCKET-AF, 336-339, 337, 338t
  - FDA-approved uses, 334
  - indications, risk category and, 296t
  - indications for, 334-335
    - in treatment algorithm, 305
- Rochester Epidemiologic Project, 23, 26
- ROCKET-AF, 336-339, 337, 338t
- Rotterdam Study, 23, 28, 57, 102
  
- SAFE-T, 122, 123, 123, 159t, 220, 235, 236
- SAFFIRE-D trial, 157t, 240
- SAVEPace trial, 103
- Scoring systems, 61, 73, 74t
  - for thromboembolism risk, 294-300, 294t, 298t
- Secondary AF, 20
  
- Sertraline, 319t
- Serum electrolytes, monitoring, 77, 79, 80
- Shock therapy. See *Electrical cardioversion*.
- Shock waveforms, 139, 140
- Sick sinus syndrome, 48t, 58, 258-260, 277
- Single-focus theory, 33
- Sinoatrial (SA) nodal cells, 13
- Sinus arrest, 142
- Sinus rhythm. See *Normal sinus rhythm (NSR)*.
- Skin effects, 219, 321
- Sleep disorders, 55, 73
- Smoking (tobacco), 57
  - cessation of, 83
- Social history, 73
- Sodium channel blockade, 206t
- Sodium channel genes, 49
- SOLVD (Studies of Left Ventricular Dysfunction), 28-29, 89-90
- Sotalol, 207t, 233-236
  - action mechanism, 207t, 233, 267
  - adverse effects, 207t, 234-235
  - clinical studies, 116, 118t-119t, 122, 125, 235-236, 236
    - CTAF, 122, 221, 222, 235-236
    - SAFE-T, 122, 123, 123, 159t, 220, 235, 236
  - contraindications/cautions, 154, 212, 235
  - dosing, 207t, 234
    - initial, 214
  - drug interactions, 235
  - implanted device threshold effects, 199t
  - indications for, 205-209, 210, 233-236
    - maintenance of NSR, 205-209, 207t, 210, 212, 234, 235-236
    - for rate control, 267
    - repeat electrical cardioversion, 143, 143t
  - initiation of therapy, 213-214, 215t
  - monitoring, 200-201, 202t-203t, 214
  - pharmacokinetics, 234
  - safety, 198, 200, 207t, 209-212
    - torsade de pointes, 197
- SPAF I trial, 76, 293, 304, 357-358
- SPAF III trial, 294, 307
- Special populations
  - acute rate control in, rate control, 275-277
  - electrical cardioversion in, 141-142
  - thromboembolism prevention in, 359-372
- SPINAF trial, 287, 293, 306
- Splenic infarction, 291t
- Spontaneous cardioversion, 150
- Sports exercise, 51, 52, 85, 322
- SSRIs, 198t, 319t
- STAF trial, 116, 118t-119t, 122



- Statins, 89, 93-98, 104  
actions of, 90t, 93  
combined with  $\beta$ -blockers, 95-98  
drug interactions, 318t  
for stroke prevention, in treatment algorithm, 305
- Stents, 397-399  
coronary stents, 371-372  
stent thrombosis, 369-370
- Steroids. See *Glucocorticosteroids*.
- STOP-2, 91
- STOP-AF, 176
- Stress (exercise) testing, 71, 72t, 77-78, 80, 203t, 204, 277-278
- Stroke, 285-288. See also *Thromboembolism*.  
age and, 286, 293t  
anticoagulation in patients presenting with, 364-365  
cardioembolic, 286-287, 288  
gender and, 293t  
ischemic, 286-288  
mortality and, 285, 288  
prevention in AF, 113, 279-352. See also *Thromboembolism*.  
algorithm for, 305  
anticoagulation therapy and, 120-121, 364-365  
clinical studies. See *SPAF I*; *SPAF III*.  
pharmacologic prevention, 303-372, 305  
prevention trials, 293-294  
prior  
in CHA2DS2-VASc score, 298t  
in CHADS2 score, 294, 294t  
risk, 292-297  
AF and, 27-28  
cardioversion and, 136  
in community patients with new-onset AF, 300-301, 302  
dronedaron and, 229, 232  
stratification schemes in AF, 292-297, 293t  
warfarin reduction of, 121, 129  
silent, 287
- Substrate for arrhythmia, 36-38, 84, 165
- Sucralfate, 319t
- Supraventricular arrhythmias, other, 57-58, 79
- Supraventricular tachycardia (SVT), 57
- Surgery, cardiac  
electrical cardioversion and, 141  
increase in AF after, 40, 57, 58-59, 59
- Surgical ablation, 184-187, 185, 270-272, 381  
AV nodal ablation with pacemaker implantation, 270-272, 277  
benefits vs risks, 186, 186t, 187, 188t  
catheter ablation and, 164-184  
complications of, 187
- Surgical ablation (*continued*)  
Cox-Maze procedure, 184-187, 185, 186t  
Cox-Maze III, 186-187, 186t, 188  
Cox-Maze IV (bipolar radiofrequency), 187-188, 187  
benefits of, 188t  
risks, 185-186, 186t, 271-272  
success rates, 184, 184t  
techniques, 166-170, 168  
variations on, 184-185
- Sympathetic nervous system/tone, 40, 48t, 73, 89
- Sympathomimetic drugs, 57, 74
- Symptoms of AF, 13, 41, 65-70, 122. See also *Clinical manifestations*.  
asymptomatic AF, 31, 65, 69  
cardioversion and, 135  
hemodynamic, 41-44  
improvement of, as goal of therapy, 122  
palpitations/fluttering, 65  
poor correlation with AF frequency/duration, 68, 78  
relief of, as goal of therapy, 109  
scoring/classification of, 73, 74t  
severe, treatment choice and, 124, 129, 129t, 133, 135
- Syncope, 65-68, 69
- Systolic blood pressure, 61
- T wave, 137
- Tachycardia  
atrial, 16, 17, 17  
AV nodal reentrant, 17  
AV reentrant, 17  
supraventricular, 57  
ventricular, 16
- Tachycardia-induced cardiomyopathy, 28, 41, 42, 65, 69, 128
- Tamoxifen, 319t
- Tamponade, 172-173, 173t
- TEE. See *Transesophageal echocardiography*.
- Telmisartan, 92
- Terfenadine, 198t
- Tetracycline, 318t
- TGF- $\beta$ , 88
- Theophylline, 54, 74
- Therapy. See also *Prevention of AF*.  
antiarrhythmic drugs, 193-252  
cardioversion, 133-192  
catheter ablation, 133, 164-184  
choice of strategy, 112, 124, 127-129, 129t  
device-based, for AF prevention, 103-104  
goals of, 109-114, 110  
acute/primary, 109, 110

Therapy, goals of (*continued*)

- long-term, 109, 110
  - individualized approach to, 109, 110, 111, 115, 126, 129, 129t, 205
  - nonpharmacologic
    - for AF prevention, 83-85, 112
    - for rate control, 269-273, 269t
    - for stroke prevention, 372-381
  - normal sinus rhythm, restoration of, 133-192
  - pharmacologic, for AF prevention, 85-102, 112
  - pharmacologic, for stroke prevention, 113
  - rate vs rhythm control, 112, 115-131, 118t-119t
  - rate control, 253-282
    - goals of, 253-257, 254t
    - nonpharmacologic therapy, 269-273, 269t
    - pharmacologic agents, 257-264
  - rhythm control, 133-252
    - antiarrhythmic drugs (AADs) for, 193-252
    - available agents, 216-248
    - catheter ablation, 133, 164-184
    - electrical cardioversion, 134-150
    - pharmacologic cardioversion, 150-164
    - surgical ablation, 184-187, 185
  - therapeutic approaches, 112-113
    - preventive therapy, 83-108, 112
    - stroke prevention, 113
      - antiplatelet therapy, 304, 357-359
      - nonpharmacologic methods, 372-381
      - surgical techniques, 381
    - surgical options, 184-187, 185, 381
- Thiazide diuretics, 198t, 238
- Thienopyridines, 369-370
- Thioridazine, 198t
- Thrombin inhibitors, direct, 304, 305, 322-334
- Thromboembolism, 27-28, 283-388. See also *Stroke*.
- AF and risk for, 27-28
  - anticoagulation therapy, duration of treatment with, 121, 124, 129, 134
  - cardioversion and, 136
  - catheter ablation and, 134
  - clinical presentation in AF, 285-288
  - cardioembolic strokes, 286-287
  - cardioversion and, 285
  - cerebral thromboembolism, 286
  - diagnosis, 287
  - immediate recognition and treatment, 285
  - ischemic stroke and TIAs, 286-288
  - other complications, 288, 290t-291t
  - outcome and mortality, 120-121, 288
  - complications, 120-121, 143

Thromboembolism (*continued*)

- CVA, 65, 69, 172
- diabetes and, 20
- low-risk patients, 297, 300
- pathophysiology in AF, 283-285
  - blood stasis, 284
  - endothelial and endocardial abnormalities, 283
  - hypercoagulable state, 28, 284-285
- peripheral, 28, 285, 288
- preventive therapies, 113, 279-352, 283-388, 296t
  - ACC/AHA/HRS Guidelines (2014), 289, 295
  - ACCP guidelines (2014), 295, 296t
  - agents available
    - aspirin, 296t, 357-358
    - dabigatran, 296t, 305, 323-334
    - warfarin, 296t, 304-322
  - anticoagulation therapy, 129, 304-372, 305
  - warfarin, 304-322
  - antiplatelet therapy, 304, 357-359
  - bleeding risk and, 306
  - LAA amputation or ligation, 381
  - newer anticoagulants, 304, 322-357
    - dabigatran etexilate, 323-334
    - factor Xa inhibitors, 304, 334-351
  - nonpharmacologic methods, 372-381
    - LAA amputation or ligation, 381
    - LAA closure devices, 372-375, 373, 374
  - in patients with AF, 296t
  - pharmacologic stroke prevention, 303-372, 305
    - basic strategies, 303-304, 305
  - special situations, 359-372
    - AF patients presenting with stroke, 364-365
    - AF patients with coronary interventions, 369-372
    - atrial flutter, 365-368
    - cardioversion of AF, 359-363
  - treatment algorithm, 305
  - warfarin, 296t, 304-322
    - alternatives to, 295
  - prothrombotic state, 284-285
  - in rate- vs rhythm-control trials, 120-121
  - risk stratification in AF, 289-303
    - age and, 286, 292, 293t
    - Birmingham scheme, 298, 298t, 300, 309
    - CHA2DS2-VASc, 298-300, 298t
    - CHADS2 score, 294-297, 294t, 300
    - clinical risk factors, 292-297, 293t
    - Framingham risk score, 300, 302
    - gender and, 293t, 298t
    - limitations of, 289

Thromboembolism, risk stratification in AF (*continued*)

- low-risk patients, 297, 300
- in new-onset AF, 300-301, 302
- preventive therapies and, 296t
- rhythm- vs rate-control, 292
- scoring systems, 294-300, 294t, 298t
- stroke prevention trials, 293-294
- stroke risk based on echocardiographic assessment, 301-303, 303t
- stroke risk in community patients with new-onset AF, 300-301, 302
- Swedish Cohort Atrial Fibrillation Study, 293t
- TTE assessment for, 76
- type of AF, 292
- valvular vs nonvalvular AF, 292
- surgical ablation and, 381
- Virchow's triad of thrombogenesis, 285

Thromboglobulin, 284-285

Thyroid conditions: hyperthyroidism, 55-56, 141-142

Thyroid hormones

- antithyroid drugs, 319t
- testing, 56, 60, 72t, 76, 79, 201

Thyrototoxicosis, 258

TIA, 286-288, 365

Ticagrelor, 371

Toes, purple/blue toe syndrome, 321

Torsade de pointes (TdP), 148

- AADs and, 148, 155, 195, 196-197, 196, 213, 238

TRACE study, 89

Trandolapril, 89

TRANSCEND study, 92

Transesophageal echocardiography (TEE), 71, 73t, 361-363

- blood stasis on, 284
- prior to cardioversion, 80, 136-137
- prior to catheter ablation, 170, 171
- stroke diagnosis with, 287
- stroke risk assessment with, 301-303, 303t
- TEE-guided cardioversion, 361-363

Transforming growth factor- $\beta$ , 88, 285

Transient ischemic attacks (TIAs), 286-288, 365

Transthoracic echocardiography (TTE), 71, 72t, 75-76, 80

- repeat, 78-79
- stroke risk assessment with, 287, 303t

Transthoracic procedure for cardioversion, 134

Treatment of AF. *See Therapy.*

Tricyclic antidepressants, 198t

Triggers of AF, 17, 33-36, 167

- prevention strategies and, 84

Trimethoprim, 238

Trimethoprim-sulfamethoxazole, 317, 318t

Triple therapy, 369-370, 371-372

TTE. *See Transthoracic echocardiography.*

UFH, 368, 370. *See also Heparins.*

Vagal predominance, 40

Vagal stimulation, 273

Vagal tone, 57, 74

Val-HeFT, 91

Valsartan, 91

VALUE trial, 91

Valvular heart disease, 53, 127, 292

- AF secondary to, 47

Vaughan-Williams classification of AADs, 206t-207t

Ventricular arrhythmias, 149

Ventricular fibrillation, 139

Ventricular proarrhythmias, 195-197, 196, 212

Ventricular rate, 14, 16, 128

- goals, with rate-control therapy, 128
- regularization with pacing, 272-273

Ventricular tachycardia, 16

Verapamil, 260-261, 262t, 278

- AF recurrence and, 205
- clinical studies, 118t-119t
- contraindications/cautions, 260-261, 324
- drug interactions, 238, 261, 264
- for rate control, 260, 262t, 274, 278
- for repeat cardioversion, 143, 143t, 146t

Vernakalant, 160-164, 164t

- action mechanism, 160-161
- approval in EU, 163
- dosing, 164t
- oral formulation, understudy, 163
- safety, 162-163
- safety and efficacy, 161-164
- side effects, 162-163, 164t
- success rate, 162, 162, 164t
- use for cardioversion, 160-164, 164t

Veterans Affairs study, 221

Virchow's triad, 285

Vitamin C, 89, 101

Vitamin E, 101

Vitamin K, 312-313, 317, 319t, 320

Vitamin K antagonists (warfarin), 303. *See also Warfarin.*

- in treatment algorithm, 305
- warfarin, 304-322

VKORC1 gene polymorphism, 316

von Willebrand factor (vWF), 283, 285

Voriconazole, 198t

Walking, 85, 86t-87t, 104  
six-minute walk test, 72t, 255, 278

Warfarin, 304-322  
action mechanism, 311  
advantages and disadvantages of, 356t  
alternatives to, 295, 351  
bleeding risk and, 306, 313-315, 317, 326-329, 328t  
  scoring systems, 314-315  
  stroke prevention and, 315, 316  
catheter ablation and, 171  
characteristics of, 310-322  
clinical trials, 304-306, 325-331  
contraindications, 372  
dosing, 312-313  
duration of treatment with, 121, 124, 129  
efficacy  
  of low-intensity warfarin, 307-310  
  in primary prevention of stroke in AF, 304-307  
  in secondary prevention of stroke in AF, 307  
indications for  
  age and, 309  
  based on CHADS2 and CHA2DS2-VASc scores, 297, 298  
  mitral stenosis, patients with, 297  
  prior to cardioversion procedures, 136  
  prior to catheter ablation, 171  
interactions, 315-321  
  cholesterol embolization, 321  
  diet, 320-321  
  drug interactions, 317-320, 318t-319t  
  genetic polymorphism, 315-316  
  herbal dietary supplements, 320, 320t  
  hypermetabolism, 321  
  pregnancy/lactation and, 321-322  
  skin necrosis, 321  
  sports activities, 322  
interruption of therapy, 370, 371  
limitations of, 309-310  
patient compliance and, 310  
in rate vs rhythm trials, 117, 120  
for stroke prevention, 120, 296t, 304-322  
  action mechanism, 311  
  bleeding risk and, 313-315, 316, 317  
  characteristics of, 210-222  
  dosing, 312-313  
  monitoring, 313, 314t  
  pharmacokinetics, 311-312  
  risk category and, 296t  
  vitamin K levels and, 312-313  
  vs dabigatran, 325-331

Warfarin (*continued*)  
  vs edoxaban, 347-351, 350  
  vs rivaroxaban, 336-339, 337, 338t

Watchman device, 372, 373, 374, 375-379

Weight loss, 83

WOEST trial, 371

Wolff-Parkinson-White (WPW) syndrome, 58, 68, 263-264, 275-277

Women's Health Study, 56-57, 101, 102

WPW syndrome. See *Wolff-Parkinson-White syndrome*.

X-ray, chest, 71, 73t, 77

Ximelagatran, 323

Young patients, 127, 128, 129, 129t, 133